每经AI快讯，2月25日，利弗莫尔中概股龙头指数盘初跌0.1%。成分股中，百济神州跌超3%，腾讯音 乐、小鹏汽车、网易跌超2%。 ...

恒生科技指数ETF（513180.SH）恒生互联网ETF（513330.SH）开年走低，权重股阿里巴巴、腾讯控 股、小米集团等再陷调整。 消息面上，春节假期，美联储降息预期下修，港股作为对外部流动性极为敏感的市场，节后表现较弱。 美国当地时间2月18日下午，美联储公布1月议息会议纪要，美联储官员对未来政策展望呈现巨大分歧， 市场认为短期内降息节奏可能放缓；2月19日，美国公布的初请失业金人数显示美国就业市场仍保持一 定韧性，而就业是降息周期中美联储重点关注的指标，基于此市场降低对美联储降息预期；2月20日， 美国公布的12月PCE高于预期，强化美联储暂缓降息预期，市场对6月降息预期下降至45.6%，降息预期 推迟至7月。 招商证券张夏团队点评称：短期美联储政策预期反复有扰动，但流动性冲击最大的阶段已经过去，且美 联储仍处降息周期，一旦降息预期重新稳固，港股作为离岸市场将显著受益；且春节后随着南下资金的 流入，也将为港股带来流动性支持。 投资工具方面，持续关注港股科技相关ETF：恒生科技指数ETF（513180.SH）、恒生互联网ETF （513330.SH）、港股通科技ETF基金（159101.SZ）。其中， ...

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the global business development (BD) activities in the pharmaceutical sector during the Chinese New Year period from February 13 to February 23, 2026, highlighting a total of 18 BD transactions globally [1] Core Insights and Arguments - **Key Transactions**: - Qinhai Bio licensed its MAT2A inhibitor (GH31), which has received IND approval in China and the US and is currently in Phase I clinical trials, to Gilead. Qinhai will receive an upfront payment of $80 million, $1.45 billion in milestone payments, and a tiered double-digit percentage royalty based on net sales [1] - Other notable transactions include: - Novartis partnered with Unnatural Products to develop macrocyclic peptide drugs, focusing on cardiovascular applications, with Unnatural Products receiving an upfront payment of $100 million and potential milestone payments of $1.7 billion [1] - Eli Lilly acquired global rights for the IL6 monoclonal antibody clazakizumab from CSL for all indications except end-stage renal disease, with CSL receiving an upfront payment of $100 million [1] - Merck collaborated with Mayo Clinic to integrate clinical and genomic data, focusing on early research translation in inflammatory bowel disease, skin diseases, and neurology [1] - **Year-to-Date Transactions**: - From January 1 to February 23, 2026, there have been 36 BD transactions involving Chinese companies, with 13 of these transactions involving multinational corporations (MNCs) [1] Additional Important Insights - **Comparison with Previous Year**: - In comparison, there were 26 BD transactions during the same period in 2025, with only 3 involving MNCs [2] - **Future Outlook**: - The analysis indicates that MNCs have increased their focus on Chinese BD teams and asset searches since the second half of 2025, suggesting a positive outlook for more BD transactions involving Chinese assets and MNCs in 2026 [2]

Core Viewpoint - BeiGene's subcutaneous formulation of Tislelizumab has received implied approval from the National Medical Products Administration for clinical trial supplementation, aimed at treating malignant tumors, marking a significant advancement in drug formulation that is expected to enhance patient compliance and market potential [1] Stock Performance - As of February 13, 2026, BeiGene's A-shares (688235) were priced at 279.62 CNY, with a 5-day cumulative increase of 2.61%; Hong Kong shares (06160) were at 208.60 HKD, up 1.66% over the same period; while U.S. shares (ONC.OQ) were at 346.07 USD, down 2.22% [2] - On February 13, 2026, A-share net outflow of main funds was 8.49 million CNY, with a trading volume of 316 million CNY, indicating short-term profit-taking pressure influenced by market sentiment and company events [2] Financial Report Analysis - BeiGene plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026; preliminary data shows a revenue of 27.595 billion CNY for the first nine months of 2025, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% year-on-year [3] - The high growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, with investors advised to focus on annual profitability and globalization progress [3] Institutional Perspectives - In the past 90 days, 9 institutions have rated BeiGene, with 8 giving a buy rating and 1 an outperform rating, setting a target average price of 320.0 CNY [4] - Analysts indicate that the company's fundamentals are robust, with strong globalization progress and profitability, although financial risks and market competition should be monitored [4]

Core Insights - The company has achieved significant global growth over the past year, marking a critical turning point towards profitability with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [1] - The company has launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotuximab), which is now commercially available [1] - The company has expanded its global footprint, with products available in over 75 markets and more than 2 million patients receiving treatment worldwide [1] Global Expansion and Market Impact - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [2] - In India, two self-developed products have benefited over 1,500 patients with positive clinical feedback [2] - The company is supporting the first immunotherapy clinical trial in sub-Saharan Africa through the provision of PD-1 inhibitors [2] - The Guangzhou production base not only serves domestic patients but also extends to markets in Indonesia, India, and South Korea, continuously expanding the company's global reach [2] Commitment to Innovation and Accessibility - The company aims to enhance drug accessibility in more countries and regions while continuing to expand its pipeline with a focus on scientific innovation [3] - The commitment to making innovative treatments available to more patients globally is seen as a long-term investment and a driving force for the company [3] Milestone Year - The year 2025 is highlighted as a milestone for the company, marking its 15th anniversary and a clearer, more determined new starting point in its globalization journey [4] Collaboration and Knowledge Sharing - The company emphasizes the importance of collaboration with various industry stakeholders to gather diverse experiences and insights, aiming to illuminate hope for more patients through scientific exploration [5]

Core Insights - Recent developments for BeiGene include the approval of a supplemental application for the subcutaneous formulation of Tislelizumab for malignant tumor treatment, which is expected to enhance patient compliance and market potential [1] - The company plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026, which will be followed by a board meeting and a conference call for investors [1] Stock Performance - BeiGene's stock has shown volatility recently, with A-shares closing at 279.62 CNY, down 1.09% on February 13, 2026, but up 2.61% over the past five days; Hong Kong shares closed at 208.60 HKD, down 0.48%, with a 1.66% increase over five days; and US shares at 350.12 USD, up 1.07% on the same day but down 1.07% over five days [2] - On February 12, 2026, A-share main funds experienced a net outflow of 18.68 million CNY, with a trading volume of 311 million CNY, indicating some profit-taking pressure amid market sentiment [2] Financial Analysis - Preliminary data shows that for the first nine months of 2025, BeiGene reported revenue of 27.595 billion CNY, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% [3] - The significant growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, and investors should pay attention to the company's profitability and globalization progress in the upcoming financial report [3]

Group 1 - The year 2025 marks a milestone for the company, celebrating its 15th anniversary and entering a clearer phase in its globalization process [2] - The company achieved significant global growth in the past year, reaching a critical profitability turning point, with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [2] - The company launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotukral), which is now commercially available [2] Group 2 - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [3] - In India, the company's two self-developed products have benefited over 1,500 patients, receiving positive clinical feedback [3] - The company is expanding its global footprint by supporting local commercialization efforts in Indonesia and providing PD-1 inhibitors for clinical trials in sub-Saharan Africa [3] Group 3 - The company's goals for 2026 remain clear: to continue pipeline expansion centered on science and to enhance drug accessibility for patients in more countries [4] - The commitment to making innovations accessible to more patients is seen as a long-term investment and a driving force for the company [4] - The company emphasizes the importance of collaboration with industry partners to gather diverse experiences and wisdom from different regions to improve patient outcomes globally [4]

Group 1 - The core viewpoint of the article highlights the performance of the CSI 500 Growth ETF managed by Huaxia Fund Management, which has seen a return of 29.67% since its inception on July 19, 2022, and a return of 0.82% over the past month [1][1][1] - As of the midday close on February 13, the CSI 500 Growth ETF (159620) fell by 0.77%, trading at 1.289 yuan with a transaction volume of 893,900 yuan [1][1][1] - The top holdings of the CSI 500 Growth ETF include stocks such as Ruichuang Micro-Nano, which rose by 0.94%, and Changchuan Technology, which increased by 2.50%, while stocks like Hehe Information and Dazhu CNC experienced declines of 1.37% and 0.15%, respectively [1][1][1] Group 2 - The performance benchmark for the CSI 500 Growth ETF is the return rate of the CSI Smart Selection 500 Growth Innovation Strategy Index [1][1][1] - The fund is managed by Huaxia Fund Management Company, with Rong Ying serving as the fund manager [1][1][1]

Financial Performance Announcement - The company, BeiGene, has announced that it will release its financial results for the fourth quarter and full year of 2025 on February 26, 2026, after the Hong Kong Stock Exchange trading hours [1][2] - The board of directors will review and approve the financial results on the same day [2] - A conference call will be held on February 26, 2026, at 8:00 AM Eastern Time (9:00 PM Hong Kong Time) to discuss the results, which will be available for investors to participate via the company's website [2] - The company expects to publish its audited annual results for 2025 by March 31, 2026, or earlier, in accordance with Hong Kong listing rules [2]

Performance and Operational Situation - The company plans to release its financial performance for the fourth quarter and the full year of 2025 on February 26, 2026, after the trading hours of the Hong Kong Stock Exchange [1] - A conference call will be held concurrently with the financial performance announcement [1] - The company expects to publish its audited annual results for 2025 by March 31, 2026, or earlier, in accordance with Hong Kong listing rules [1]